

Thomas R Chauncey

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8529277/thomas-r-chauncey-publications-by-year.pdf>

Version: 2024-04-29

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

162
papers

11,513
citations

53
h-index

107
g-index

170
ext. papers

12,217
ext. citations

3.7
avg, IF

4.95
L-index

#	Paper	IF	Citations
162	Proteogenomic Characterization of Highly Enriched Viable Leukemic Blasts in Acute Myeloid Leukemia: A SWOG Report. <i>Blood</i> , 2021 , 138, 522-522	2.2	
161	Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. <i>Haematologica</i> , 2021 , 106, 1599-1607	6.6	6
160	Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 176-181	2	4
159	Long-term Outcomes with Nonmyeloablative HLA-Identical Related Hematopoietic Cell Transplantation Using Tacrolimus and Mycophenolate Mofetil for Graft-versus-Host Disease Prophylaxis. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 163.e1-163.e7		
158	Autologous hematopoietic transplantation following COVID-19 infection. <i>Clinical Case Reports (discontinued)</i> , 2021 , 9, 1167-1170	0.7	1
157	Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors. <i>Blood</i> , 2020 , 136, 1499-1506	2.2	7
156	Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS). <i>Case Reports in Hematology</i> , 2020 , 2020, 8811673	0.7	5
155	AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report. <i>Biomarker Research</i> , 2020 , 8, 29	8	6
154	Phase I/II multisite trial of optimally dosed clofarabine and low-dose TBI for hematopoietic cell transplantation in acute myeloid leukemia. <i>American Journal of Hematology</i> , 2020 , 95, 48-56	7.1	1
153	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. <i>Bone Marrow Transplantation</i> , 2020 , 55, 172-181	4.4	8
152	Mantle cell lymphoma relapsed after autologous stem cell transplantation: a single-center experience. <i>Blood Research</i> , 2020 , 55, 57-61	1.4	1
151	Assessing Cachexia Acutely after Autologous Stem Cell Transplant. <i>Cancers</i> , 2019 , 11,	6.6	5
150	Total body irradiation dose escalation decreases risk of progression and graft rejection after hematopoietic cell transplantation for myelodysplastic syndromes or myeloproliferative neoplasms. <i>Haematologica</i> , 2019 , 104, 1221-1229	6.6	9
149	Second allogeneic hematopoietic cell transplantation for relapse after first allografts. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1758-1766	1.9	5
148	Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2019 , 6, e409-e418	14.6	53
147	Impact of Neurocognitive Dysfunction in a Veteran Population Undergoing First Outpatient Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Blood</i> , 2019 , 134, 5883-5883 ^{2,2}		
146	Ibrutinib in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Final Results from a Prospective Phase II Study. <i>Blood</i> , 2019 , 134, 1596-1596	2.2	1

145	Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report. <i>Blood</i> , 2019 , 134, 2691-2691	2.2	
144	Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial. <i>Blood</i> , 2019 , 134, 369-369	2.2	
143	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <i>Haematologica</i> , 2019 , 104, 380-391	6.6	19
142	Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies. <i>Blood</i> , 2018 , 131, 2782-2788	2.2	13
141	Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 308-313	4.7	5
140	Ibrutinib Is Effective in Relapsed or Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma: Results from a Prospective Phase II Study. <i>Blood</i> , 2018 , 132, 2954-2954	2.2	
139	Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report. <i>Biopreservation and Biobanking</i> , 2018 , 16, 42-52	2.1	5
138	Allogeneic Hematopoietic Cell Transplantation (HCT) in the Eighth Decade of Life: How Much Does Age Matter?. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, S98-S99	4.7	2
137	CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017 , 23, 405-411	4.7	8
136	Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 380-385	4.7	28
135	Sirolimus Combined with Mycophenolate Mofetil (MMF) and Cyclosporine (CSP) Significantly Improves Prevention of Acute Graft-Versus-Host-Disease (GVHD) after Unrelated Hematopoietic Cell Transplantation (HCT): Results from a Phase III Randomized Multi-Center Trial. <i>Blood</i> , 2016 , 128, 506-506	2.2	3
134	Adding peri-transplant rituximab to nonmyeloablative (NMA) conditioning before allogeneic hematopoietic cell transplantation (allo-HCT) to improve disease-related outcomes in patients with chronic lymphocytic leukemia (CLL): Phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7052-7052	2.2	
133	Reversal of Low Donor Chimerism Following Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion. <i>Blood</i> , 2016 , 128, 2215-2215	2.2	
132	Comparable Outcomes of Patients Eligible Versus Ineligible for Southwest Oncology Group (SWOG) Leukemia Studies. <i>Blood</i> , 2016 , 128, 4002-4002	2.2	
131	Improved Prognostic Significance of Genomic and Transcriptional Biomarkers By Examining Enriched Populations of AML Blasts: A SWOG Report. <i>Blood</i> , 2016 , 128, 2890-2890	2.2	
130	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1582-1587	4.7	12
129	Fibrosing cholestatic hepatitis C after hematopoietic cell transplantation: report of 3 fatal cases. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 212-20	6.7	22
128	Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity. <i>Leukemia and Lymphoma</i> , 2015 , 56, 92-6	1.9	5

127	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. <i>British Journal of Haematology</i> , 2015 , 171, 788-97	4.5	10
126	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Cancer</i> , 2015 , 121, 3709-16	6.4	22
125	A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience. <i>Blood</i> , 2015 , 126, 1949-1949	2.2	
124	CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. <i>European Journal of Haematology</i> , 2014 , 93, 77-80	3.8	26
123	A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. <i>Haematologica</i> , 2014 , 99, 1624-31	6.6	32
122	Rituximab Maintenance Therapy after Autologous Stem Cell Transplantation Improves Survival of Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2014 , 124, 3985-3985	2.2	2
121	Long Term Follow-up of High-Dose CD20-Targeted Radioimmunotherapy-Based Autologous Transplantation for Patients with Mantle Cell Lymphoma. <i>Blood</i> , 2014 , 124, 3967-3967	2.2	
120	Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 949-57	4.7	61
119	Fludarabine and 2-Gy TBI is superior to 2 Gy TBI as conditioning for HLA-matched related hematopoietic cell transplantation: a phase III randomized trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1340-7	4.7	20
118	Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013 , 19, 1403-6	4.7	22
117	Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1530-8	2.2	164
116	Umbilical Cord Blood Transplant Patients At High Risk Of Graft Rejection Achieve Early Full Donor Chimerism When 300cGy Is Used In The Reduced Intensity Conditioning Regimen. <i>Blood</i> , 2013 , 122, 697-697	2.2	1
115	Impact Of Pre-Transplant Rituximab Sensitivity In Relapsed Follicular Lymphoma On Outcome After Autologous Transplant. <i>Blood</i> , 2013 , 122, 3365-3365	2.2	
114	The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. <i>Blood</i> , 2012 , 119, 2657-64	2.2	116
113	Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. <i>Blood</i> , 2012 , 119, 2675-8	2.2	49
112	Cytomegalovirus viral load and virus-specific immune reconstitution after peripheral blood stem cell versus bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 66-75	4.7	23
111	Limiting the daily total nucleated cell dose of cryopreserved peripheral blood stem cell products for autologous transplantation improves infusion-related safety with no adverse impact on hematopoietic engraftment. <i>Biology of Blood and Marrow Transplantation</i> , 2012 , 18, 220-8	4.7	8
110	Allo-SCT for multiple myeloma: a review of outcomes at a single transplant center. <i>Bone Marrow Transplantation</i> , 2012 , 47, 1312-7	4.4	22

109	Randomized Comparison of Melphalan 200 Mg/m2 v. 280 Mg/m2 As a Preparative Regimen for Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 2009-2009	2.2	1
108	The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 4195-4195	2.2	1
107	Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts. <i>Blood</i> , 2012 , 120, 4207-4207	2.2	1
106	Specific Features Identify Patients with Relapsed/Refractory Mantle Cell Lymphoma Benefitting From Autologous Hematopoietic Cell Transplantation.. <i>Blood</i> , 2012 , 120, 3082-3082	2.2	
105	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. <i>Blood</i> , 2012 , 120, 354-354	2.2	
104	Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3023-9	2.2	58
103	Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 1874-83	27.4	216
102	Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. <i>Haematologica</i> , 2011 , 96, 1113-20	6.6	82
101	Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes. <i>Blood</i> , 2011 , 118, 319-319	2.2	3
100	The Pre-Transplant Mantle Cell Lymphoma International Prognostic Index Predicts Overall and Progression-Free Survival Following High-Dose Therapy and Autologous Stem Cell Transplant for Mantle Cell Lymphoma. <i>Blood</i> , 2011 , 118, 2026-2026	2.2	1
99	Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data. <i>Blood</i> , 2011 , 118, 1446-1446	2.2	
98	Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010 , 148, 48-58	4.5	24
97	Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2859-67	2.2	163
96	Low-dose total body irradiation and fludarabine conditioning for HLA class I-mismatched donor stem cell transplantation and immunologic recovery in patients with hematologic malignancies: a multicenter trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010 , 16, 384-94	4.7	38
95	Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2010 , 116, 2364-2364	2.2	2
94	International Working Group Scores Predict Post-Transplant Outcomes In Patients with Myelofibrosis. <i>Blood</i> , 2010 , 116, 3085-3085	2.2	4
93	A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.. <i>Blood</i> , 2010 , 116, 3450-3450	2.2	1
92	Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors. <i>Blood</i> , 2010 , 116, 1292-1292	2.2	

91	Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010 , 116, 2365-2365	2.2	
90	What is the role for donor natural killer cells after nonmyeloablative conditioning?. <i>Biology of Blood and Marrow Transplantation</i> , 2009 , 15, 580-8	4.7	50
89	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. <i>Blood</i> , 2009 , 113, 3383-91	2.2	87
88	A Randomized 3-Arm Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute Graft-Versus-Host Disease (GVHD) After Unrelated Donor Hematopoietic Cell Transplantation (HCT) Using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies: A Multi-Center Trial. <i>Blood</i> , 2009 , 114, 348-348	2.2	4
87	Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. <i>British Journal of Haematology</i> , 2008 , 143, 395-403	4.5	87
86	Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 246-55	4.7	111
85	Pretransplant neutropenia is associated with poor-risk cytogenetic features and increased infection-related mortality in patients with myelodysplastic syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2008 , 14, 799-806	4.7	20
84	Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Journal of Clinical Oncology</i> , 2008 , 26, 4912-20	2.2	228
83	Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 211-7	2.2	172
82	Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. <i>Cancer</i> , 2008 , 112, 1992-2001	6.4	199
81	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2008 , 112, 149-149	2.2	4
80	Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Blood</i> , 2007 , 110, 2744-8	2.2	147
79	Nonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 423-32	4.7	34
78	Extended mycophenolate mofetil and shortened cyclosporine failed to reduce graft-versus-host disease after unrelated hematopoietic cell transplantation with nonmyeloablative conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 1041-8	4.7	19
77	Long-Term Outcome of Autologous Followed by Nonmyeloablative Allografting from HLA-Identical Sibling for Multiple Myeloma (MM).. <i>Blood</i> , 2007 , 110, 3029-3029	2.2	1
76	Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed Diffuse Large B-Cell Lymphoma (DLBCL).. <i>Blood</i> , 2007 , 110, 3037-3037	2.2	
75	Duration of Immunosuppressive Therapy for Chronic Graft-vs.-Host Disease (cGVHD) Following Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).. <i>Blood</i> , 2007 , 110, 1071-1071	2.2	
74	Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4150-7	2.2	88

73	Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. <i>Journal of Clinical Oncology</i> , 2006 , 24, 444-53	2.2	220
72	Treatment for acute myelogenous leukemia by low dose Total Body Irradiation (TBI) based conditioning and hematopoietic cell transplantation from related and unrelated donors. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 31-32	4.7	105
71	Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: the effect of postgrafting mycophenolate mofetil dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2006 , 12, 454-65	4.7	79
70	Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. <i>Transplantation</i> , 2006 , 81, 818-25	1.8	35
69	Nonmyeloablative Hematopoietic Cell Transplantation. <i>Annals of the New York Academy of Sciences</i> , 2006 , 938, 328-339	6.5	55
68	Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. <i>Leukemia</i> , 2006 , 20, 128-35	10.7	202
67	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) for Refractory Waldenström Macroglobulinemia (WM): Evidence for a Graft-Versus-WM Effect.. <i>Blood</i> , 2006 , 108, 3034-3034 ^{2,3}		
66	Outcomes of c Hematopoietic Stem Cell Transplantation (HCT) after Non-Myeloablative Conditioning in Relapsed, Refractory, or Transformed Indolent Non-Hodgkin Lymphoma (NHL).. <i>Blood</i> , 2006 , 108, 3124-3124	2.2	1
65	Postgrafting Immunosuppression with Prolonged Mycophenolate Mofetil (MMF) and Truncated Cyclosporine (CSP) Failed To Reduce the Incidence of Graft-Versus-Host Disease (GVHD) after Unrelated Donor Hematopoietic Cell Transplantation (HCT) with Nonmyeloablative Conditioning.. <i>Blood</i> , 2006 , 108, 3119-3119	2.2	
64	Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 85-92	4.7	49
63	Assessing donor chimerism level among CD3 T, CD4 T, CD8 T, and NK cells predicts subsequent graft rejection, GVHD, and relapse after allogeneic HCT with nonmyeloablative conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 11	4.7	6
62	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 272-9	4.7	44
61	Effects of race on survival after stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2005 , 11, 231-9	4.7	36
60	Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. <i>British Journal of Haematology</i> , 2005 , 128, 659-675	4.5	56
59	Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2005 , 129, 381-91	4.5	38
58	Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up. <i>British Journal of Haematology</i> , 2005 , 130, 747-51	4.5	89
57	High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. <i>Leukemia</i> , 2005 , 19, 822-8	10.7	90
56	Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. <i>Leukemia</i> , 2005 , 19, 990-7	10.7	52

55	Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1993-2003	2.2	277
54	Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3819-29	2.2	191
53	Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2409-17	1.9	25
52	Autologous bone marrow transplantation improves disease free survival but not overall survival in people with acute myeloid leukaemia. <i>Cancer Treatment Reviews</i> , 2004 , 30, 483-7	14.4	1
51	HLA-matched related (MRD) or unrelated donor (URD) nonmyeloablative conditioning and hematopoietic cell transplant (HCT) for patients with advanced Hodgkin disease (HD). <i>Biology of Blood and Marrow Transplantation</i> , 2004 , 10, 73-74	4.7	62
50	Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. <i>Blood</i> , 2004 , 103, 790-5	2.2	113
49	Kinetics of engraftment in patients with hematologic malignancies given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Blood</i> , 2004 , 104, 2254-62	2.2	210
48	Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma. <i>Blood</i> , 2004 , 104, 3535-42	2.2	227
47	Transplantation for adult ALL: Typing and timing. <i>Blood</i> , 2004 , 104, 2998-2999	2.2	1
46	Unrelated Donor Peripheral Blood Stem Cell (PBSC) Transplantation Using Nonmyeloablative Conditioning and Mycophenolate Mofetil (MMF) TID Results in High Engraftment Rates.. <i>Blood</i> , 2004 , 104, 1818-1818	2.2	3
45	Conversion of Low Donor Chimerism Following Nonmyeloablative Conditioning for Hematopoietic Cell Transplantation (HCT) Using Pentostatin and Donor Lymphocyte Infusion (DLI).. <i>Blood</i> , 2004 , 104, 186-186	2.2	4
44	Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.. <i>Blood</i> , 2004 , 104, 3074-3074	2.2	2
43	Allogeneic Hematopoietic Cell Transplantation after Fludarabine and 2 Gy Total Body Irradiation for Relapsed and Refractory Mantle Cell Lymphoma.. <i>Blood</i> , 2004 , 104, 809-809	2.2	1
42	Nonmyeloablative Conditioning and Hematopoietic Cell Transplantation (HCT) from HLA-Matched Related or Unrelated Donors for Chemotherapy-Refractory Chronic Lymphocytic Leukemia (CLL).. <i>Blood</i> , 2004 , 104, 2323-2323	2.2	
41	Graft-versus-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning.. <i>Blood</i> , 2004 , 104, 184-184	2.2	
40	Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.. <i>Blood</i> , 2004 , 104, 2316-2316	2.2	1
39	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. <i>Blood</i> , 2003 , 102, 3912-8	2.2	228
38	Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. <i>Blood</i> , 2003 , 101, 1620-9	2.2	387

37	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. <i>Blood</i> , 2003 , 102, 3447-54	2.2	346
36	HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. <i>Blood</i> , 2003 , 102, 2021-30	2.2	308
35	HLA-matched related hematopoietic cell transplantation for chronic-phase CML using a targeted busulfan and cyclophosphamide preparative regimen. <i>Blood</i> , 2003 , 102, 31-5	2.2	150
34	Relapse or progression after hematopoietic cell transplantation using nonmyeloablative conditioning: effect of interventions on outcome. <i>Experimental Hematology</i> , 2003 , 31, 974-80	3.1	24
33	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2003 , 120, 281-8	4.5	80
32	Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 266-72	4.7	26
31	Predictive factors for outcome of allogeneic hematopoietic cell transplantation for adult acute lymphoblastic leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2003 , 9, 472-81	4.7	68
30	Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. <i>International Journal of Hematology</i> , 2002 , 76 Suppl 1, 184-9	2.3	20
29	Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donors. <i>Transfusion</i> , 2002 , 42, 1414-21	2.9	101
28	Engraftment of early erythroid progenitors is not delayed after non-myeloablative major ABO-incompatible haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2002 , 119, 740-50	4.5	26
27	Nonmyeloablative hematopoietic cell transplantation: status quo and future perspectives. <i>Journal of Clinical Immunology</i> , 2002 , 22, 70-4	5.7	26
26	Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. <i>Blood</i> , 2002 , 100, 1201-7	2.2	253
25	Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study. <i>Blood</i> , 2002 , 99, 1978-85	2.2	197
24	Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1409-14	1.9	16
23	Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 161-9	4.7	55
22	Infectious complications after autologous CD34-selected peripheral blood stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 281-9	4.7	72
21	Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. <i>Biology of Blood and Marrow Transplantation</i> , 2002 , 8, 512-20	4.7	206
20	CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. <i>Blood</i> , 2001 , 98, 3221-7	2.2	208

19	Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. <i>Blood</i> , 2001 , 98, 586-93	2.2	66
18	Relapse after allogeneic bone marrow transplantation for refractory anemia is increased by shielding lungs and liver during total body irradiation. <i>Biology of Blood and Marrow Transplantation</i> , 2001 , 7, 163-70	4.7	20
17	Non-myeloablative hematopoietic stem cell transplantation. <i>Transfusion Clinique Et Biologique</i> , 2001 , 8, 231-4	1.9	19
16	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. <i>Blood</i> , 2001 , 97, 3390-400	2.2	1183
15	Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. <i>New England Journal of Medicine</i> , 2001 , 344, 175-81	59.2	831
14	Drug resistance mechanisms in acute leukemia. <i>Current Opinion in Oncology</i> , 2001 , 13, 21-6	4.2	36
13	Bile duct apoptosis and cholestasis resembling acute graft-versus-host disease after autologous hematopoietic cell transplantation. <i>American Journal of Surgical Pathology</i> , 2000 , 24, 1004-8	6.7	49
12	A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. <i>Leukemia Research</i> , 2000 , 24, 567-74	2.7	56
11	Granulocyte colony-stimulating factor given to donors before apheresis does not prevent aplasia in patients treated with donor leukocyte infusion for recurrent chronic myeloid leukemia after bone marrow transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2000 , 6, 321-6	4.7	29
10	Allogeneic hematopoietic stem cell transplantation: from the nuclear age into the twenty-first century. <i>Transplantation Proceedings</i> , 2000 , 32, 2548-9	1.1	11
9	A Phase I-II Clinical Trial to Evaluate Removal of CD4 Cells and Partial Depletion of CD8 Cells From Donor Marrow for HLA-Mismatched Unrelated Recipients. <i>Blood</i> , 1999 , 94, 2192-2199	2.2	83
8	Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. <i>New England Journal of Medicine</i> , 1998 , 338, 962-8	59.2	541
7	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997 , 89, 3880-3887	2.2	117
6	Improved Reconstitution of CD4 T Cells and B Cells But Worsened Reconstitution of Serum IgG Levels After Allogeneic Transplantation of Blood Stem Cells Instead of Marrow. <i>Blood</i> , 1997 , 89, 3891-3892	2.2	43
5	Transplantation of Marrow Cells From Unrelated Donors for Treatment of High-Risk Acute Leukemia: The Effect of Leukemic Burden, Donor HLA-Matching, and Marrow Cell Dose. <i>Blood</i> , 1997 , 89, 4226-4235	2.2	334
4	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 1997 , 90, 4705-4709	2.2	288
3	Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis. <i>British Journal of Haematology</i> , 1997 , 98, 1010-6	4.5	60
2	Cyclosporine or Cyclosporine Plus Methylprednisolone for Prophylaxis of Graft-Versus-Host Disease: A Prospective, Randomized Trial. <i>Blood</i> , 1997 , 89, 3880-3887	2.2	3

1	Allogeneic Peripheral Blood Stem Cell Transplantation May Be Associated With a High Risk of Chronic Graft-Versus-Host Disease. <i>Blood</i> , 1997 , 90, 4705-4709	2.2	7
---	---	-----	---